Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations-Reference-Cited by-同舟云学术

Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations

Published:2020-02 Issue:2 Volume:156 Page:363-376
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Solsky Ian,Chen Jinbo,Rebbeck Timothy R.

Funder

NIH

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference40 articles.

1. Meta-analysis of BRCA1 and BRCA2 penetrance;Chen;J. Clin. Oncol.,2007

2. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer;Berek;Obstet. Gynecol.,2010

3. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality;Domchek;Jama,2010

4. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation;Kauff;N. Engl. J. Med.,2002

5. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry;Piver;Cancer,1993

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients;Cancers;2022-03-23

2. Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy;Journal of Gynecologic Oncology;2022

3. Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location;Genes;2021-07-08

4. Corrigendum to “Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations” [Gynecologic Oncology 156 (2020) 363–376];Gynecologic Oncology;2021-05